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Abstract
Objective
In this work we set to develop and to validate a new in vivo frameless orthotopic Diffuse
Intrinsic Pontine Glioma (DIPG) model based in the implantation of a guide-screw system.
Methods
It consisted of a guide-screw also called bolt, a Hamilton syringe with a 26-gauge needle
and an insulin-like 15-gauge needle. The guide screw is 2.6 mm in length and harbors a 0.5
mm central hole which accepts the needle of the Hamilton syringe avoiding a theoretical dis-
placement during insertion. The guide-screw is fixed on the mouse skull according to the
coordinates: 1mm right to and 0.8 mm posterior to lambda. To reach the pons the Hamilton
syringe is adjusted to a 6.5 mm depth using a cuff that serves as a stopper. This system
allows delivering not only cells but also any kind of intratumoral chemotherapy, antibodies or
gene/viral therapies.
Results
The guide-screw was successfully implanted in 10 immunodeficient mice and the animals
were inoculated with DIPG human cell lines during the same anesthetic period. All the mice
developed severe neurologic symptoms and had a median overall survival of 95 days rang-
ing the time of death from 81 to 116 days. Histopathological analysis confirmed tumor into
the pons in all animals confirming the validity of this model.
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Conclusion
Here we presented a reproducible and frameless DIPG model that allows for rapid evalua-
tion of tumorigenicity and efficacy of chemotherapeutic or gene therapy products delivered
intratumorally to the pons.
Introduction
Diffuse Intrinsic Pontine Gliomas (DIPGs) represent the most frequent tumor among brain-
stem gliomas and constitute a real challenge for everyone devoted to the treatment of pediatric
brain tumors[1,2]. Since its first description in the twentieth century, therapeutic alternatives
remain scarce[3]. A dismal median overall survival between 9 to 13 months has remained
unchanged in spite of combination of radiotherapy with targeted therapies. Unlike other
brainstem tumors that benefit from surgical treatment such as focal pontine gliomas, exophy-
tic, tectal or cervicomedullary tumors, DIPG due to its diffuse nature and anatomic extension
within the pons, remains a fatal neoplasm[4]. Up to now the diagnosis was based on specific
clinical symptoms and a characteristic radiographic appearance which usually shows a diffuse
enlargement of the pons along with a variable and irregular contrast enhancement pattern.
Thanks to the advent of biopsies which have led to an understanding of the genetic makeup of
these tumors as well as generation of cell lines, several in vivo models have been recently devel-
oped including murine models that recapitulates the genotype of theses tumors[5–8] Most of
these models employ stereotaxic-guided systems. The main advantage of using stereotaxy con-
sists of precise access to the pons region throughout a biopsy needle aimed to a specific region
in the brainstem according to previous standard coordinates. However, to perform studies
with a high number of animals, such as survival studies with new therapeutic strategies or
delivery of gene therapy agents, which need to be injected intratumorally, stereotaxy is
extremely time-consuming, even in the hands of experienced researchers. In addition, if serial
subsequent injections need to be performed there is the risk that they do not fall exactly in the
same place.
In this work we set out to develop a rapid and reproducible DIPG model that recapitulates
the histopathological features of diffuse pontine tumors but without the need of stereotaxic
surgery. Previously, Lal et al described an implantable guide-screw system that allowed for
rapid and consistent establishment of intracranial glioma xenografts that made consecutive
intratumoral injection of potential therapies feasible [9]. Based on this approach we developed
a DIPG xenograft that employs a guide-screw system inserted in the mice skull according to
posterior fossa anatomic landmarks and directed to the pontine area. This model allows us not
only for the generation of tumors in a fast and reproducible fashion but also to deliver thera-
peutic agents such as oncolytic viruses or immunomodulatory approaches, amongst others,
through the screw fixed system.
Materials and Methods
Description of the guide-screw system
The guide-screw system was developed by the group of Dr. Fred Lang (UT MD Anderson
Cancer Center, TX) [9] to study the effects of gene therapy on supratentorial intracranial glio-
mas xenografts avoiding the use of a stereotactic frame. Briefly, it consisted of a guide-screw
also called bolt (#C212SG, Plastics One) a Hamilton syringe with a 26-gauge needle and an
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insulin-like 15-gauge needle. The guide screw is 2.6 mm in length and harbors a 0.5 mm cen-
tral hole which accepts the needle of the Hamilton syringe avoiding a theoretical displacement
during insertion. This system allows delivering not only cells but also any kind of intratumoral
chemotherapy, antibodies or gene/viral therapy, etc.
The aim of this work was to develop a guide-screw based system specifically adapted to gen-
erate DIPG tumors without the use of a stereotactic frame.
Establishment of DIPG coordinates
First, we set to establish the coordinates for generation of DIPG tumors using the Allen brain
atlas. In addition, we use the Allen brain atlas to rule out the possibility that mice brain struc-
tures could be affected by Hamilton introduction (Fig 1A). We localize our entry point
1.0 mm right to lambda and just posterior (0.8 mm) to lambdoid suture (Fig 1B) so that large
draining veins from posterior sinus can be avoided away from the target point [10].
Next, we assess the feasibility of the guide-screw placement using those coordinates and
whether it would keep securely fixed over time (Fig 1C). We successfully inserted the guide-
screw in the coordinates and it stayed secured for at least 30 days. Finally, it was necessary to
establish the depth coordinate in order to generate the tumors in the right area inside of the
pons. We injected an ink-based solution using a Hamilton syringe (26-gauge needle) fitted
with a cuff at different depths ranging between 5-7mm (Fig 1D). This experiment allowed us
to define the definitive coordinates to reach the pons: 1mm right to and 0.8 mm posterior to
lambda as well as 6.5 mm depth insertion (Fig 1E).
Technique for screw insertion
Under aseptic conditions and with all materials sterilized according to standard techniques,
mice of four weeks of age were anesthetized by intraperitoneal injection with ketamine and
xilacyne solution. The animal heads were supported by a couple of rolled gauzes so that when
the screw was inserted, pressure applied over neck and head structures was better tolerated by
the animal.
We prepared mice head skin with povidone iodine solution prior to make a 5 mm-long lin-
eal skin incision with 23-size scalpel and expose both sagittal and lambdoid sutures. We first
made a small mark according to the coordinates mentioned above with a small 15-gauge nee-
dle which was subsequently widened with a hand-controlled twist drill (Drill HSS, #8J60 Plas-
tics One) which penetrates the skull until it reaches the duramater. At this point some bleeding
from epidural space venous plexus could appear in some animals although constant pressure
applied over the entry point with swabs should stop the bleeding. Next, we introduced the
screw with its specific screwdriver by applying slight pressure throughout the previous twist
hole until it was flushed with the cranial surface so that distal portion has protruded through
duramater a few mm into brainstem area due to the particular configuration of brainstem in
mice.
Cell preparation and implantation
Once the screw was precisely inserted we proceeded with cell inoculation immediately after
bolt insertion and during the same anesthetic period. We performed both procedures at the
same time to reduce discomfort to the animal and to save time. Thereafter the needle of Ham-
ilton syringe is slowly introduced into the hole by applying gentle pressure until the sleeve/cuff
from the syringe reaches the screw surface and the desired depth (6.5 mm) is targeted. Roughly
10 minutes after bolt insertion, cell suspension (106 cells in 3μl/per animal) was carefully
injected using an infusion pump (Harvard Apparatus) over 20 minutes into the pontine
Guide-Screw Protocol
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Fig 1. Screw guide system used to target the brainstem. A. Mouse Allen Brain Atlas scheme of brain structures, upper
image is 3D image of mouse brain, left lower image is a sagittal scheme and right lower image represents a coronal image, bold
dash line marks pons area in each image. B. Bolt coordinates in relation with lambda and sagittal sutures. C. Photo of mouse
skull with bolt positioned in DIPG coordinates. D. Macroscopic photograph of ink solution injected at 6.5mm of depth with a
Hamilton syringe through the bolt. E. Schematic drawing of screw guide components used in this administration method.
doi:10.1371/journal.pone.0170501.g001
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region. With this technique the likelihood of reflux during cell administration was significantly
reduced. At the end the needle was gently removed and the wound was closed with special sur-
gical glue (Hystoacryl #1050044, Braum Surgical) so no sutures were required. Furthermore,
recovery after surgical procedure is quicker and more comfortable because only one anesthetic
dosage per animal was employed. At the end of the procedure all animals received an appro-
priate dosage of morphine solution as analgesic and waked up from anesthesia under warm
conditions.
Animal progression after surgery
Since animals were exposed to a highly invasive surgery they needed two days of analgesics. In
addition we administered hydrant gels and gathered their food on the cage floor in order to
facilitate food ingestion and accelerate mice recovery. Total mice recovery was achieved 72
hours after surgery with no visible symptoms caused by the procedure. Occasionally, some
transient gait problems were observed in some animals during the first 48 hours after surgery
that resolved spontaneously. No weigh loss was observed after surgery in any of the mice.
Cell lines
For cell implantation we used the TP54 cell line derived from a biopsy of a patient with a
DIPG tumor [11]. This cell line is characterize by a mutation in p53 (R248Q) a mutation in the
K27M of H3F3A and is wild type for PTEN and ACVR1. Cell line were grown as neurospheres
in a specific serum-free medium (NeuroCult™ NS-A Proliferation Kit, Human, #05751 Stem
Cell Technologies) supplemented with EGF and bFGF in a humidified atmosphere of 5% CO2
at 37˚C as previously described[11].
Animal studies
Athymic mice were obtained from Harlan Laboratories (Barcelona; ES). Mice were maintained
at the Centro de Investigacio´n Medica Aplicada (CIMA; Pamplona; Spain) in specific patho-
gen-free conditions and fed standard laboratory chow. The study was approved by the com-
mittee of bioethics (CEEA; Comite´ E´tico de Experimentacio´n Animal under the protocol
number CEEA/077-13). All animal studies were done in the veterinary facilities of the Center
for Applied Medical Research in accordance with institutional, regional, and national laws and
ethical guidelines for experimental animal care. The animals were monitored on daily basis
and were euthanized when they demonstrate moribund behaviour including: slight head tilt,
hemiparesis, hunched posture, scleral edema, inability to access food/water, weight loss >20%
of baseline, and excessive tumor burden as indicated by doming of cranium >0.5 cm, or if
show signs of lower extremity weakness. The animals were sacrificed with CO2 inhalation. To
minimize suffering of the animals, ketamine/xylazine or buprenorphine was given for signs of
pain, eye wincing, hunched state with front limbs over the head.
Immunohistochemical analysis
Paraffin-embedded sections of mouse brains were immunostained with specific antibodies for
H3K27M mutant (#ABE419 Millipore, 1:500), GFAP (Dako, Z0344 rabbit polyclonal, 1:500),
human Nestin (#ABD69 Millipore, 1:500), Olig2 (#AB9610 Millipore, 1:500), Ki67 clone SP6
(Thermo Scientific, RM9106, 1:100) and human Vimentin clone V9, (M0725, Dako Denmark
A/S, 1:400). Conventional procedures were followed in all cases.
Guide-Screw Protocol
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Results
Tumor development, follow up and survival of mice bearing DIPG
orthotopic xenografts
To validate the development of a frameless reproducible brainstem tumor model we injected
the DIPG TP54 cells using our guide-screw system into the pons of nude mice (N = 10)
according to the protocol described above. Animals were visually and physically checked for
symptoms every two days during the first 4 weeks and daily beyond 30 days after surgical
intervention. In addition, to rule out the possibility of brain damage magnetic resonance (3
Tesla MRI, Siemens Magnetom Trio and Magnetom Skyra) was performed to 5 random ani-
mals 15 days after surgery. MRI images showed no sign of damage or tumor at this early time
point. We performed another MRI at a later time in these same animals when we observed
symptoms compatible with tumor development in the pons such as animals spinning around
themselves, showing gait disturbances and/or weight loss. In all these mice we found MRI
images compatible with pontine tumors. In particular, in one of these animals besides the
tumor (T) the images showed hydrocephaly (H) secondary to ventricular obstruction caused
by the tumor[12] (Fig 2A).
Using the guide-screw engrafting technique 10 out of 10 mice developed tumors that
resulted in progressive symptoms compatible with pons invasion. Animals bearing the TP54
cells in the pons had a median overall survival of 95 days ranging the time of death from 81 to
116 days (Fig 2B). Mice brains were extracted and tumors were detectable even macroscop-
ically right into the core of the pons (Fig 2C).
Pathological analyses of DIPG tumors
Next, we performed pathological analyses to characterize the tumors developed with our sys-
tem. Hematoxylin–eosin staining of mice brains revealed that all tumors were localized in the
pons (Fig 3A). Some of the tumors showed growth towards the cerebellar peduncles. The
hematoxylin eosin staining showed a highly cellular and poorly differentiated tumor, com-
posed by monotonous large and rounded cells with central nuclei and prominent nucleoli (Fig
3B). Several mitotic figures could be recognised. Vascular proliferation and necrosis were not
evident in the tumor. Brain not affected by the tumor showed a normal morphology (Fig 3B).
Immunohistochemistry analyses showed positive staining for the H3K27 mutation, an
aberration found in 80% of DIPGs tumors, in almost all cells (Fig 3C). Additionally, we ana-
lysed this mutation by western blot using the same antibody. As expected we corroborated the
mutation in the H3K27M in the Tp54 cell line (Fig 3C). Tumor cells showed a glial phenotype
as cytoplasmic expansions stained with GFAP. The nuclear staining against olig2 reinforces
the glial character of the neoplasm (Fig 3D and 3E). It was previously described that these cells
exhibited a neural profile expressing neural stem cells markers[11] including nestin and
vimentin (Fig 3F and 3G). In addition, the tumor showed an intense proliferative activity
according to the Ki67 immunoreactivity. Ki67 was found in 60 to 80% of the cells depending
on the area evaluated (Fig 3H).
We have developed a reproducible and frameless DIPG model that allows for rapid evalua-
tion of tumorigenicity, chemotherapeutic or gene therapy products delivered intratumorally to
the pons.
Discussion
Several years ago tissue sampling was not thought to be neither necessary nor suitable because
of the potential mortality and morbidity associated with the biopsy process. The paucity of
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therapeutic alternatives led to redefine DIPG patients0 management in order to obtain a better
understanding of the pathobiological pathways that would allow for more adequate treatment.
Fortunately, the advent of technical breakthroughs, new biopsy protocols and interinstitu-
tional collaborations has allowed a surge in research in this devastating disease including the
development of several in vivo DIPG models [13–15].
Our group work is focused on the development of oncolytic viral and immune-therapies
for pediatric brain tumors including DIPGs. Therefore, we needed a reproducible, fast tech-
nique that allowed not only for a reproducible engraftment of the cells in the pons but also for
a system that facilitates the posterior delivery of different therapeutic agents into the tumor in
the same area. Stereotaxy has proven as a secure and feasible system to develop preclinical
DIPG models [5,6,16]. In fact, several groups have shown the validity of this technique to
develop orthotopic DIPG tumors[2] that recapitulates the biology and phenotype of this
Fig 2. Tp54 tumor development in nude mice. A. Representative MRI of tumor development, left, central and right represent, respectively, sagittal,
transverse and coronal views of a 3D T2-weighted sequence. Tumor (T) is seen as a hypointense dot in the pons, and hydrocephaly (H) caused by tumor
pressure is seen as hyperintense dilatation of the mice ventricular system. B. Kaplan–Meier survival curve analysis for overall survival in athymic mice
bearing DIPG xenografts tumors originated by engraftment of 106 TP54 cells. C. Macroscopically image of mice brain with a visible tumor in the pons.
doi:10.1371/journal.pone.0170501.g002
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disease. However, when there are a big number of animals per experiment due to a wide vari-
ety of treatment schedules or tested agents or the therapeutic agent needs to be delivered intra-
tumorally stereotaxic technique, although precise, is extremely time-consuming. With this
scenario in mind, the implantable guide-screw system developed by Dr. Lang at MD Anderson
for brain tumor studies in small animals[9] provided the perfect system for the sequential
delivery of different agents to the same anatomic region. Therefore, we used the guide-screw
system to generate a DIPG model. A similar mode in rats was previously used by Hashizume
et al [17]. In our study we adapted the system to be used in mice and we described the method
in-depth for its feasible reproduction by other authors. The main advantage of employing this
guide-screw system in the posterior coordinates that resemble children´s real DIPG location is
the consistent cell delivery to the same area without the stereotaxic frame fact that saves a lot of
time without compromising reproducibility and animal well-being. In addition, this procedure
facilitates the delivery of therapeutic agents that are administered intratumorally, such as onco-
lytic adenoviruses, without the need of further surgery. As a result, this system allows for
Fig 3. Pathological analyses of tumors developed by the TP54 cell line. A. Hematosilin-eosin stained of sagittal section of mice brain (x50) B. Right,
tumor micrography image of hematosilin-eosin stained tumor section (400x). Left, detail of normal mouse brain (400x). Tp 54 tumor immunohistochemistry
staining(400x): C. against Histone 3 mutation in lysine 27 and western blot, D. Glial Fibrillary Acid Protein (GFAP), E. Olig 2, F. Nestin, G. Vimentin and H.
Ki67.
doi:10.1371/journal.pone.0170501.g003
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standardization of experiments when several groups are needed, facilitates tumor engraftment
and the intratumorally delivery of different therapeutic agents in a reproducible and fast way.
Conclusions
In this work we developed a preclinical in vivo DIPG model based on a guide-screw system
fixed over mice skull that is feasible and allows for reproducible DIPG tumor generation in a
fast and consistent fashion. This system permits the use of a considerable amount of animals
for experiment and allows for the subsequent intratumoral injection of different therapeutic
agents.
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